査読有
doi：10.1038/s41598-024-70928-z
PubMed No.：39215078
2023 Impact Factor：3.8
種類：原著
誌名：Scientific Reports
発行年月：2024年8月
巻号頁：14: 20200, 2024
論題：Impact of metformin, statin, aspirin and insulin on the prognosis of uHCC patients receiving first line Lenvatinib or Atezolizumab plus Bevacizumab
著者：Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Toshifumi Tada, Goki Suda, Shigeo Shimose, Sara Lonardi, Fabian Finkelmeier, Francesca Salani, Lorenzo Antonuzzo, Fabio Marra, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Rodolfo Sacco, Ilario Giovanni Rapposelli, Mario Scartozzi, Pella Nicoletta, Luca Aldrighetti, Mara Persano, Silvia Camera, Federico Rossari, Silvia Foti, Takashi Kumada, Atsushi Hiraoka, Hideki Iwamoto, Mario Domenico Rizzato, Vera Himmelsbach, Gianluca Masi, Mattia Corradi, Ciro Celsa, Conti Fabio, Giovanni Luca Frassineti, Stefano Cascinu, Andrea Casadei-Gardini, Jose Presa
